This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

McCormick & Schmick's Poison Pill And Buyout For $8.75 Per Share Prompts Stockholder Investigation By Goldfarb Branham Law Firm LLP Securities Lawyers

DALLAS, Nov. 9, 2011 /PRNewswire/ -- Goldfarb Branham LLP is investigating whether certain officers and directors of McCormick & Schmick (NASDAQ: MSSR) violated shareholder protection laws by agreeing to sell the company for $8.75 per share. Concerned investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

"Earlier this year, McCormick & Schmick's board adopted a "poison pill" to block a takeover after rejecting a $9.25 share offer from rival Landry's," said Hamilton Lindley. "Our proposed class action lawsuit seeks to ensure that the McCormick & Schmick shareholders receive the best value reasonably available and a fair process in this buyout."  

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. McCormick & Schmick investors – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

Hamilton Lindley Goldfarb Branham LLP2501 N. Harwood, Ste. 1801 Dallas, TX 75201(877) 583-2855 Toll Free Telephone (214) 583-2233 Local Phone Number (214) 583-2234 Fax Number hlindley@goldfarbbranham.com www.goldfarbbranham.com

SOURCE Goldfarb Branham LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs